|
AU2015360502A1
(en)
|
2014-12-10 |
2017-06-29 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
HK1254190A1
(zh)
|
2015-05-08 |
2019-07-12 |
President And Fellows Of Harvard College |
通用供体干细胞和相关方法
|
|
JP2018536436A
(ja)
|
2015-12-04 |
2018-12-13 |
ノバルティス アーゲー |
免疫腫瘍学のための組成物および方法
|
|
MX2019008413A
(es)
*
|
2017-01-13 |
2019-09-13 |
Univ California |
Celulas pluripotentes inmunodiseñadas.
|
|
EP3601528A4
(en)
*
|
2017-03-20 |
2021-05-05 |
Washington University |
CELLS AND METHODS OF USE AND PRODUCTION OF THEM
|
|
MX2019011272A
(es)
|
2017-03-22 |
2019-10-24 |
Novartis Ag |
Composiciones y metodos para inmunooncologia.
|
|
IL270835B2
(en)
|
2017-06-12 |
2025-01-01 |
Sinai Health Sys |
Allograft tolerance without the need for systemic immunosuppression
|
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
SG11202100157YA
(en)
*
|
2018-07-17 |
2021-02-25 |
Univ California |
Cells differentiated from immunoengineered pluripotent cells
|
|
JP2021530999A
(ja)
*
|
2018-07-17 |
2021-11-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
免疫改変多能性幹細胞由来のキメラ抗原受容体ｔ細胞
|
|
US10724052B2
(en)
*
|
2018-09-07 |
2020-07-28 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
WO2020067993A1
(en)
*
|
2018-09-26 |
2020-04-02 |
National University Of Singapore |
Engineered human mesenchymal stromal cells with low immunogenicity, methods and kits of generating the same
|
|
UY38427A
(es)
*
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
|
CN111424016A
(zh)
*
|
2019-01-09 |
2020-07-17 |
复旦大学 |
降低细胞免疫原性的诱导型多能干细胞系及建立方法
|
|
AU2020223192A1
(en)
*
|
2019-02-15 |
2021-09-09 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
SG11202112506SA
(en)
*
|
2019-05-10 |
2021-12-30 |
Univ California |
Modified pluripotent cells
|
|
AU2020307550A1
(en)
|
2019-06-26 |
2022-02-03 |
The Regents Of The University Of California |
SIRPalpha-silenced natural killer (NK) cells
|
|
TW202115245A
(zh)
*
|
2019-06-27 |
2021-04-16 |
丹麥商諾佛 儂迪克股份有限公司 |
安全免疫隱形細胞
|
|
EP4022037A1
(en)
|
2019-07-10 |
2022-07-06 |
Helmuth Heinrich Kunz |
Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro
|
|
JP2022543112A
(ja)
*
|
2019-08-01 |
2022-10-07 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｄｕｘ４発現細胞およびそれらの使用
|
|
EP4017508A1
(en)
|
2019-08-23 |
2022-06-29 |
Sana Biotechnology, Inc. |
Cd24 expressing cells and uses thereof
|
|
US11118195B2
(en)
|
2019-09-05 |
2021-09-14 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
AU2020340622A1
(en)
|
2019-09-05 |
2022-03-03 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
JP7696335B2
(ja)
*
|
2019-09-09 |
2025-06-20 |
スクライブ・セラピューティクス・インコーポレイテッド |
免疫療法に使用するための組成物および方法
|
|
WO2021055985A1
(en)
*
|
2019-09-22 |
2021-03-25 |
Cellerant Therapeutics, Inc. |
Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
|
|
US20240091274A1
(en)
*
|
2019-10-15 |
2024-03-21 |
The Regents Of The University Of California |
TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION
|
|
CA3164591A1
(en)
*
|
2020-01-13 |
2021-07-22 |
William Dowdle |
Modification of blood type antigens
|
|
US20230058557A1
(en)
|
2020-01-15 |
2023-02-23 |
The Regents Of The University Of California |
Transplanted cell protection via inhibition of polymorphonuclear cells
|
|
KR20220142433A
(ko)
*
|
2020-01-17 |
2022-10-21 |
사나 바이오테크놀로지, 인크. |
유전자 발현 조절용 안전 스위치
|
|
MX2022011831A
(es)
|
2020-03-25 |
2023-01-04 |
Sana Biotechnology Inc |
Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas.
|
|
JP2023521157A
(ja)
*
|
2020-04-06 |
2023-05-23 |
アールエックスセル インコーポレーテッド |
低免疫原性の細胞ならびにそれらの産生のための方法および組成物
|
|
AU2021259612A1
(en)
*
|
2020-04-21 |
2022-11-10 |
Intima Bioscience, Inc. |
Cellular vaccine platform and methods of use
|
|
EP4149525A4
(en)
*
|
2020-05-15 |
2024-08-28 |
Rxcell Inc. |
HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES
|
|
MX2023001831A
(es)
|
2020-08-13 |
2023-06-29 |
Sana Biotechnology Inc |
Métodos de tratamiento de pacientes sensibilizados con células hipoinmunogénicas y métodos y composiciones asociados.
|
|
CN112342196A
(zh)
*
|
2020-08-18 |
2021-02-09 |
未来智人再生医学研究院(广州)有限公司 |
一种免疫兼容可逆的通用型多能干细胞及其应用
|
|
KR20230110258A
(ko)
*
|
2020-10-20 |
2023-07-21 |
리플레이 홀딩스, 인크. |
세포 요법을 위한 방법 및 조성물
|
|
CN114457021A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd47抗体的多能干细胞及其衍生物与应用
|
|
CN114525255A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-11的多能干细胞衍生物及其应用
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
AU2021392032A1
(en)
|
2020-12-03 |
2023-06-22 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
CN114107211B
(zh)
*
|
2020-12-04 |
2025-09-30 |
未来智人再生医学研究院(广州)有限公司 |
一种多能干细胞及其衍生物
|
|
CN116829698A
(zh)
*
|
2020-12-07 |
2023-09-29 |
加利福尼亚大学董事会 |
通过SIRP-α衔接体的先天免疫细胞沉默
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
AU2021414405A1
(en)
|
2020-12-31 |
2023-08-10 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
KR20230137900A
(ko)
|
2020-12-31 |
2023-10-05 |
사나 바이오테크놀로지, 인크. |
Car-t 활성을 조정하기 위한 방법 및 조성물
|
|
US20220296572A1
(en)
|
2021-03-03 |
2022-09-22 |
Sana Biotechnology, Inc. |
Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
|
|
EP4306634A4
(en)
*
|
2021-03-09 |
2025-03-26 |
Riken |
METHOD FOR PRODUCING HYPOIMMUNOGENIC RETINAL PIGMENT EPITHELIAL CELLS
|
|
CA3213361A1
(en)
*
|
2021-03-30 |
2022-10-06 |
Tobias Deuse |
Transplanted cell protection via modified fc receptors
|
|
AU2022281328A1
(en)
*
|
2021-05-24 |
2023-12-07 |
Sangamo Therapeutics, Inc. |
Ciita targeting zinc finger nucleases
|
|
KR20240013135A
(ko)
|
2021-05-27 |
2024-01-30 |
사나 바이오테크놀로지, 인크. |
조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포
|
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
KR102847814B1
(ko)
*
|
2021-07-28 |
2025-08-21 |
의료법인 성광의료재단 |
B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
IL310702A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
EP4384544A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
CN113801881B
(zh)
*
|
2021-08-27 |
2024-02-20 |
浙江大学 |
超级增强子基因序列在促进人b2m基因表达中的用途
|
|
EP4419117A1
(en)
|
2021-10-22 |
2024-08-28 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
AU2022422147A1
(en)
|
2021-12-23 |
2024-07-04 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
|
EP4479084A1
(en)
|
2022-02-14 |
2024-12-25 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
KR20240155390A
(ko)
|
2022-02-17 |
2024-10-28 |
사나 바이오테크놀로지, 인크. |
조작된 cd47 단백질 및 이의 용도
|
|
US20250101382A1
(en)
|
2022-03-11 |
2025-03-27 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
CN114958768B
(zh)
*
|
2022-06-02 |
2023-03-24 |
健颐生物科技发展(山东)有限公司 |
Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
|
|
CN117343962A
(zh)
*
|
2022-06-29 |
2024-01-05 |
中国科学院上海营养与健康研究所 |
免疫兼容型人多能干细胞、其制备方法及应用
|
|
MA71320A
(fr)
|
2022-07-01 |
2025-04-30 |
Novo Nordisk A/S |
Amélioration de la différenciation neuronale de cellules progénitrices neurales du mésencéphale ventral
|
|
WO2024012420A1
(zh)
*
|
2022-07-11 |
2024-01-18 |
士泽生物医药（苏州）有限公司 |
一种表达faslg的通用型细胞及其制备方法
|
|
CN117431217A
(zh)
*
|
2022-07-12 |
2024-01-23 |
上海驯鹿生物技术有限公司 |
表达靶向cd5的嵌合抗原受体(car)的细胞及其应用
|
|
GB202211117D0
(en)
*
|
2022-07-29 |
2022-09-14 |
Replay Holdings Llc |
Compositions and methods for non-immunogenecity
|
|
GB202212144D0
(en)
*
|
2022-08-19 |
2022-10-05 |
Resolution Therapeutics Ltd |
Cells for therapy
|
|
WO2024097313A1
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods for producing t cell therapy products
|
|
EP4619015A1
(en)
*
|
2022-11-15 |
2025-09-24 |
The Board of Trustees of the Leland Stanford Junior University |
Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine
|
|
CN118207165A
(zh)
*
|
2022-12-07 |
2024-06-18 |
士泽生物医药（苏州）有限公司 |
一种表达stc1的通用型细胞及其制备方法
|
|
CN118147077B
(zh)
*
|
2022-12-07 |
2025-09-26 |
士泽生物医药（苏州）有限公司 |
一种表达gsn的通用型细胞及其制备方法
|
|
GB202218755D0
(en)
*
|
2022-12-13 |
2023-01-25 |
Replay Holdings Llc |
Compositions and methods for non-immunogenicity
|
|
WO2024125592A1
(zh)
*
|
2022-12-16 |
2024-06-20 |
士泽生物医药（苏州）有限公司 |
一种通用型细胞及其制备方法
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
CN118497129A
(zh)
*
|
2023-02-16 |
2024-08-16 |
士泽生物医药（苏州）有限公司 |
通用型细胞及其制备方法
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025003393A1
(en)
|
2023-06-30 |
2025-01-02 |
Novo Nordisk A/S |
Enhancing neuronal differentiation of neural progenitor cells
|
|
KR102740042B1
(ko)
*
|
2023-07-12 |
2024-12-06 |
㈜바이오솔빅스 |
인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
CN119351338A
(zh)
*
|
2023-09-15 |
2025-01-24 |
士泽生物医药（苏州）有限公司 |
一种表达cd300ld的低免疫原性细胞及其制备方法
|
|
WO2025096757A1
(en)
|
2023-11-01 |
2025-05-08 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025230947A1
(en)
|
2024-04-30 |
2025-11-06 |
Satellite Biosciences, Inc. |
Engineered hepatocytes for secreting polypeptides
|
|
WO2025230941A1
(en)
|
2024-04-30 |
2025-11-06 |
Satellite Biosciences, Inc. |
Hypoimmunogenic cell mixtures and methods of use thereof
|